
Please try another search
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination. In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling. Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Lindy Gillian Durrant | 68 | 2008 | Chief Scientific Officer, Director & Founder |
Susan Elizabeth Clement-Davies | 63 | 2020 | Independent Non-Executive Deputy Chair |
Ursula Mary Ney | 73 | 2019 | Independent Non-Executive Director |
Sathijeevan Nirmalananthan | 39 | 2023 | CFO, Company Secretary & Director |
Florian Nicolas Christian Reinaud | 52 | 2024 | Non-Executive Director |
Martin Henry Diggle | 63 | 2019 | Non-Executive Director |
Jean-Michel Yves Sylvain Cossery | 66 | 2023 | Non-Executive Chairman |
Phillip John L’Huillier | 63 | 2024 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review